Hongyin Wang, MD
Internal Medicine · Williston Park, NYNPI 1831465558
Payments from drug & device makers
Across 295 payments — averaging $27.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$4K
- Amgen$700
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$503
- AstraZeneca$453
- AbbVie$436
- Lilly USA, LLC$434
- plus $2K from 18 others
What the payments were for
- Consulting fees$2,10026%
- Food & beverage$5,94874%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 62 | $3,612 |
| Amgen | 30 | $700 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 29 | $503 |
| AstraZeneca | 23 | $453 |
| AbbVie(2 entities) | 18 | $436 |
| Lilly USA, LLC | 28 | $434 |
| Merck | 23 | $368 |
| Boehringer Ingelheim | 16 | $345 |
| Amarin Pharma, Inc. | 12 | $278 |
| Novo Nordisk | 20 | $265 |
| GSK | 9 | $199 |
| Phathom Pharmaceuticals, Inc. | 7 | $154 |
| Pfizer | 5 | $91 |
| Seqirus USA Inc | 2 | $32 |
| Ironwood Pharmaceuticals, Inc | 2 | $30 |
| Radius Health, Inc. | 1 | $23 |
| Genentech USA, Inc. | 1 | $20 |
| Circassia Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| IBSA Pharma Inc. | 1 | $16 |
| Dynavax Technologies Corporation | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| VBI Vaccine (delaware) Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,057 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 378 | $254,203 |
| VascepaIcosapent Ethyl | 631 | $229,970 |
| Diclofenac Epolamine | 168 | $111,179 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 130 | $82,556 |
| OzempicSemaglutide | 85 | $81,928 |
| ProliaDenosumab | 37 | $61,827 |
| Diclofenac Sodium | 137 | $58,450 |
| ForteoTeriparatide | 13 | $56,057 |
| FarxigaDapagliflozin Propanediol | 81 | $53,569 |
| LinzessLinaclotide | 90 | $47,078 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 18 | $41,997 |
| EliquisApixaban | 65 | $39,836 |
| JanuviaSitagliptin Phosphate | 60 | $35,586 |
| RybelsusSemaglutide | 31 | $28,058 |
| Repatha SureclickEvolocumab | 42 | $22,985 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Jentadueto, Combivent Respimat | $345 | $267,475406 claims |
| Novo NordiskOzempic, Rybelsus | $265 | $109,986116 claims |
| GSKTrelegy Ellipta, Arexvy, Shingrix | $199 | $104,037218 claims |
| AmgenProlia, Evenity (2 Syringes) | $700 | $103,82355 claims |
| AbbVieLinzess, Creon, Restasis | $436 | $68,246115 claims |
| AstraZenecaFarxiga, Brilinta | $453 | $59,37894 claims |
| Lilly USA, LLCForteo | $434 | $56,05713 claims |
| PfizerEliquis | $91 | $39,83665 claims |
| MerckJanuvia, Janumet Xr | $368 | $38,75472 claims |
| GileadVemlidy | $3,612 | $21,69915 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $503 | $5,74011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Williston Park
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.